Chancellor of the Exchequer, Rachel Reeves, has announced a £520 million (US$675 million) investment for manufacturing capacity in the United Kingdom, prompting academic and industry leaders to point out that funds should be used to train personnel.
Artur - stock.adobe.com
Editor's note: this story was originally published on PharmTech.com.
Following an announcement by Chancellor of the Exchequer, Rachel Reeves, that there will be £520 million (US$675 million) made available in the United Kingdom's Autumn Budget, members of the academia and industry in the UK spoke up on the need for training within the pharma manufacturing field. Reeves had announced that the funding was aimed at developing drug manufacturing capabilities in the UK (1). The budgetary allocation of the funds starts with an increase in manufacturing capacity so that the UK can better respond to healthcare emergencies, however, some are emphasizing that the funds would be important for training personnel.
“This announcement in the Budget to support life sciences is a welcome step for the UK medicines manufacturing sector,” said Professor Ivan Wall, co-director of Resilience, the UK’s first Medicines Manufacturing Skills Centre of Excellence, in a press release (2). “However, there is an acute skills shortage that must be addressed to ensure we have trained staff ready to work in the sector.”
Resilience, which was created to address the shortage of skills in the pharmaceutical industry within the UK, is a two-year project funded by the Office for Life Sciences in the UK Government’s Department for Science, Innovation & Technology that is managed through Innovate UK. The center’s interest, as would be expected, is to ensure that talent is being focused on. Resilience will be providing industry training courses that address issues such as digital technology, artificial intelligence, data analysis, and environmental sustainability. The center will be partnering with universities across the UK to develop the program, which will include in-person and remote training courses for advanced laboratory and manufacturing skills at the academic level.
“A major consideration for success in building this capability will be in ensuring a strong supply of talent to maximize productivity across new facilities,” said Wall in the release. “Talent is in short supply across the UK Life Sciences sector and that is where projects like Resilience can help, by building the ecosystem to maintain a strong, internationally competitive sector and ensure patients have access to the best drugs through the NHS [National Health Service].”
Sustainability is also a goal of the center. “There is a great opportunity to design with environmental sustainability principles embedded,” Wall said. “Around 25% of NHS emissions are in the supply chain, so our approach using VR [virtual reality] training will reduce plastics and other waste, helping the industry deliver net zero medicines manufacturing.”
1. HM Treasury. Autumn Budget 2024: Fixing the Foundations to Deliver Change. Report (October 2024).
2. Resilience. UK’s Medicines Manufacturing Skills Centre Welcomes Budget’s £520 million for Manufacturing but Says the Priority Must be Skills Development. Press Release. Nov. 6, 2024.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.